Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950) Meeting Abstract
| Authors: | Stacchiotti, S.; Schoffski, P.; Jones, R.; Agulnik, M.; Villalobos, V. M.; Jahan, T. M.; Chen, T. W. W.; Italiano, A.; Demetri, G. D.; Cote, G. M.; Chugh, R.; Attia, S.; Gupta, A. A.; Loggers, E. T.; Van Tine, B.; Sierra, L.; Yang, J.; Rajarethinam, A.; Gounder, M. M. |
| Abstract Title: | Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 562s |
| Language: | English |
| ACCESSION: | WOS:000487345804100 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2019.37.15_suppl.11003 |
| Notes: | Meeting Abstract: 11003 -- Source: Wos |
